Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

664
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
664
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

868
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
868
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.3K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

511
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
511
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI).

Arthritis care & research·2026
Same author

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Bone marrow transplantation·2026
Same author

Inflammatory signatures in the spectrum of myeloid diseases.

HemaSphere·2026
Same author

Identification of DNA sequence variants in the Vasculo-Behcet disease patient using whole exome sequencing: a pilot study from Pakistan.

Scientific reports·2026
Same author

Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.

The World Allergy Organization journal·2026
Same author

Decoding variants of uncertain significance in systemic autoinflammatory diseases.

Nature reviews. Rheumatology·2026

Related Experiment Video

Updated: Mar 2, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.4K

Interleukin-1 Blockade: An Update on Emerging Indications.

Anoop Mistry1, Sinisa Savic2,3, Jeroen C H van der Hilst4,5

  • 1Department of Clinical Immunology and Allergy, St. James's University Hospital, Wellcome Trust Brenner Building, Beckett Street, Leeds, UK.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|May 13, 2017
PubMed
Summary

Interleukin-1 (IL-1) is crucial in inflammation but inappropriately produced in autoinflammatory diseases like gout, where IL-1 blockade is effective. In other conditions, IL-1 plays a minor role, showing limited benefits from blockade.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

7.0K

Related Experiment Videos

Last Updated: Mar 2, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.4K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

7.0K

Area of Science:

  • Immunology
  • Cytokine Biology
  • Inflammation Research

Background:

  • Interleukin-1 (IL-1) is a pro-inflammatory cytokine essential for host defense against pathogens and tissue repair.
  • Dysregulated IL-1 production is implicated in the pathogenesis of various inflammatory and autoimmune conditions.
  • Understanding the specific role of IL-1 in different diseases is critical for targeted therapeutic strategies.

Purpose of the Study:

  • To delineate the role of IL-1 in the etiology of diverse clinical conditions.
  • To evaluate the therapeutic efficacy of IL-1 blockade in diseases with inappropriate IL-1 production versus those where IL-1 is a secondary factor.
  • To differentiate disease contexts where IL-1 blockade is highly effective from those with minimal or absent benefits.

Main Methods:

  • Review and synthesis of existing clinical data and research findings on IL-1's role in disease.
  • Analysis of patient cohorts with autoinflammatory diseases (e.g., gout, Schnitzler's syndrome, adult-onset Still's disease) and other conditions (e.g., diabetes, cardiovascular disease, neurological disorders, neoplastic diseases).
  • Assessment of the clinical outcomes associated with IL-1 blockade therapies in these diverse disease settings.

Main Results:

  • High levels of inappropriate IL-1 production are a key etiological factor in autoinflammatory diseases.
  • IL-1 blockade demonstrates significant therapeutic efficacy in conditions characterized by inappropriate IL-1 production.
  • In diseases like type 1 and 2 diabetes mellitus, acute coronary syndrome, amyotrophic lateral sclerosis, and certain cancers, IL-1 is present but not the primary driver of inflammation, yielding minimal benefits from IL-1 blockade.

Conclusions:

  • IL-1 blockade is a highly effective treatment for autoinflammatory diseases driven by inappropriate IL-1.
  • The therapeutic success of IL-1 blockade is contingent on the specific disease's underlying inflammatory mechanisms.
  • Targeting IL-1 is beneficial only when it is a central etiological factor in the disease process.